Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

  • Choose the service you want to log in to:

  • gov.je

    Update your notification preferences

  • one.gov.je

    Access government services

  • CAESAR

    Clear goods through customs or claim relief

  • Talentlink

    View or update your States of Jersey job application

Changes to Prescribed List (Jersey) as of 1 September 2019

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 12 July 2019

Decision Reference: MD-S-2019-0051

Decision Summary Title :

DS_Changes to Prescribed List as of 1 Sept 2019

Date of Decision Summary:

9 July 2019

Decision Summary Author:

Policy Principal

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

N/A

Written Report

Title :

WR_Report PBAC 20 June 2019

Date of Written Report:

9 July 2019

Written Report Author:

Policy Principal

Written Report :

Public or Exempt?

Public

Subject: Changes to be made to the Prescribed List (Jersey) as of 1 September 2019

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 September 2019 as set out in the accompanying report.

Reason(s) for Decision:  The Pharmaceutical Benefit Advisory Committee met on 20 June 2019 and has provided the Minister with recommendations and the accompanying written report regarding amendments to the Prescribed List.

Items to be added to the Prescribed List

  • Ganciclovir eye ointment 0.1% to replace discontinued aciclovir eye ointment
  • Nifedipine modified release capsules 20mg, 30mg, 60mg to allow all brands/manufacturers
  • Latanoprost and timolol unit dose eye drops 50micrograms/5mg
  • Vaginal lubricants (brands Sylk, YES; excludes pre-filled applicators)
  • Bismuth subsalicylate 17.5mg/mL oral suspension (generic only) to replace discontinued tripotassium dicitratobismuthate (De-Nol)

 

Other changes to the Prescribed List

  • Remove aciclovir eye ointment 3%
  • Remove tripotassium dicitratobismuthate (De-Nol) that is now discontinued
  • Remove lidocaine gel 2% as rarely prescribed and only available as special manufactured product.
  • Allow all brands and manufacturers for nifedipine modified-release tablets and capsules 20mg, 30mg, 60mg

 

The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund.

Resource Implications:  The overall financial impact of the above changes is expected to be cost neutral with the possibility of a very small reduction in total expenditure.

Action required:  Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

Position:

Minister

Date Signed:

 

Date of Decision (If different from Date Signed):

 

Back to top
rating button